FDA drug class
CD22-directed Immunoconjugates list
Every FDA-approved prescription drug the FDA NDC directory tags with the CD22-directed Immunoconjugate [EPC] class, with brand names and DEA schedules.
Source: FDA NDC Directory file dated 2026-10-22. Publisher page
The FDA NDC directory lists 1 single-ingredient drug in this class: inotuzumab ozogamicin.
Run it in Rivvi
Map Besponsa and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
CD22-directed Immunoconjugates (1)
| Drug | Brand names | Type | NDC listings | DEA schedule |
|---|---|---|---|---|
| Inotuzumab ozogamicin | Besponsa | Single ingredient | 1 | Not controlled |
FDA established pharmacologic class: CD22-directed Immunoconjugate [EPC].
Questions
What drugs are CD22-directed Immunoconjugates?
The FDA NDC directory lists 1 single-ingredient drug in this class: inotuzumab ozogamicin.
Where does this list come from?
From the established pharmacologic class (EPC) field FDA publishes for each listing in the NDC directory. A drug is listed when most of its prescription listings carry the class.